Introduction {#sec1}
============

With progressing age, there are fundamental changes in the immune system and the propensity for abnormal immunity \[[@B1]\]. Individuals who are more than 50 years of age are not only more susceptible to infection and cancer, but are also at a higher risk of chronic inflammation. The process of immunosenescence is accelerated in rheumatoid arthritis (RA) \[[@B1]\], a systemic autoimmune disease \[[@B2]\] characterized by chronic progressive articular inflammation. Despite its low prevalence \[[@B3]\], no significant reduction in mortality has been demonstrated in different RA populations worldwide \[[@B4],[@B5]\]. Multiple factors could affect the development of RA \[[@B3]\], and the etiology and pathogenesis of RA are not completely understood. However, several lines of observational evidence have indicated that osteoclasts and monocytic cells are key mediators of the bone loss which occurs during the course of RA. As members of the tumor necrosis factor (TNF) family, the receptor activator of nuclear factor-κB (RANK), its ligand RANKL, and osteoprotegerin (OPG, a decoy receptor of RANK) are known to have significant impacts on the central regulation of osteoclast development and activation \[[@B6],[@B7]\]. A previous study identified that single nucleotide polymorphisms (SNPs) located on *RANK, RANKL* and *OPG* were associated with the presence of anti-citrullinated peptide antibody (ACPA) or erosions in RA patients \[[@B8]\]. Moreover, the application of anti-rheumatic drugs has been shown to modulate the expression of RANKL and OPG by the synovial tissue in RA, thus preventing cartilage and bone damage. Thus, we hypothesized that the RANK, RANKL and OPG network may play an important role in the pathogenesis of RA.

The association between the *RANK* gene, *RANKL* gene, *OPG* gene SNPs and RA susceptibility may provide new research directions for RA studies. Thus far, several studies \[[@B9]\] have explored the relationship between polymorphisms in the *RANK* and *RANKL* genes but achieved conflicting and inconclusive results. As gene pools, lifestyle, and gene--environment interactions vary between populations, we cannot expect risk to be identical across every population with respect to genotypes. Therefore, we conducted this case-controlled study to investigate the association between *RANK* gene rs1805034 polymorphism and RA susceptibility in a Chinese Han population. We also realized that a single case-controlled study may not have full statistical power and may lead to inconclusive results owing to limited sample sizes, clinical heterogeneity and different ethnic populations. Therefore, we further performed an additional meta-analysis to verify the relationship between known SNPs in the *RANK, RANKL* and *OPG* genes and RA and thus yielded more robust conclusions.

Methods {#sec2}
=======

Study population {#sec2-1}
----------------

This hospital-based case-controlled study was approved by the Ethics Committee of the Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University and performed according to the *Declaration of Helsinki*.

In total, 574 hospitalized RA patients (427 females and 147 males) were recruited from the Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, the Changzhou Traditional Chinese Medical Hospital and the Changzhou First Hospital. These patients were diagnosed using the criteria published by the American College of Rheumatology/European League against Rheumatism Collaborative Initiative for RA \[[@B17]\]. Patients of other nationalities, with other major systemic diseases, other autoimmune diseases, or a family history of autoimmune diseases were all excluded.

The 804 controls (500 females and 205 females) were patients without RA, matched for age and sex and were recruited from the same institutions during the identical period. Most of the controls were trauma patients. In order to acquire information relating to demographic data and related risk factors, each patient was interviewed personally using a pre-tested questionnaire; this was done after patients had provided written informed consent.

Genomic DNA extraction and genotyping {#sec2-2}
-------------------------------------

Ethylenediaminetetraacetic acid (EDTA) tubes were used to store blood samples. Genomic DNA was isolated from whole blood using a QIAamp DNA blood mini kit (Qiagen, Hilden, Germany). SNPs were genotyped by a MassARRAY system (Sequenom, San Diego, California) and by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) which was performed without knowledge of patient status (case *vs.* control) to ensure the quality of genotyping, as previously described \[[@B18]\].

Statistical analysis {#sec2-3}
--------------------

The relationship between the studied SNPs and RA risk was accessed by calculating the odds ratio (OR) and 95% confidence intervals (CI) for five gene models (allele, dominant, recessive, homozygous, and heterozygous). Demographic characteristics and the genotypes of the studied genes were evaluated using a chi-squared (χ^2^) test (for categorical variables) or Student's *t* test (for continuous variables). All statistical analyses were performed on SAS software package (ver. 9.1.3; SAS Institute, Cary, NC, U.S.A.) with a significance level of *P*\<0.05. Hardy--Weinberg equilibrium (HWE) of the genotypes was analyzed using the goodness-of-fit χ^2^ test, to compare the observed and expected genotype frequencies among controls. To thoroughly investigate the association of SNPs in the genes of *RANK, RANKL* and *OPG* with RA, we also conducted a meta-analysis which was performed using the Stata 11.0 software (StataCorp, College Station, TX, U.S.A.).

Results {#sec3}
=======

Clinical details of the study population {#sec3-1}
----------------------------------------

The characteristics of the study population are summarized in [Table 1](#T1){ref-type="table"}. Cases and controls were well matched in terms of age and sex (*P*=0.080 and *P*=0.962, respectively), and no significant differences in age and sex were observed between the RA patients and controls. The frequency distribution of the rs1805034 genotypes in the RA patients and control subjects are shown in [Table 2](#T2){ref-type="table"} and conformed to the HWE in each group.

###### Patient demographics and risk factors in RA

  Variable                     Cases (*n*=574)   Controls (*n*=804)   *P*
  ---------------------------- ----------------- -------------------- -------
  Age (years)                  54.5 ± 15.1       55.7 ± 10.1          0.080
  Female/male                  427/147           599/205              0.962
  Onset age (years)            45.6 ± 12.9                            
  Disease duration (years)     8.9 ± 9.2                              
  Treatment duration (years)   7.6 ± 7.8                              
  RF-positive                  456 (79.4%)                            
  ACPA positive                300 (52.2%)                            
  CRP-positive                 323 (56.3%)                            
  ESR (mm/h)                   33.7 ± 25.2                            
  DAS28                        4.3 ± 1.5                              
  Functional class                                                    
  I                            73 (12.7%)                             
  II                           256 (44.6%)                            
  III                          209 (36.4%)                            
  IV                           36 (6.3%)                              

Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; DAS28, RA disease activity score; RF, rheumatoid factor.

###### Logistic regression analysis of associations between rs1805034 polymorphism and the risk of RA

  Genotype         Cases (*n*=574)   Controls (*n*=804)   OR (95% CI), *P*   Adjusted OR (95% CI); *P*                              
  ---------------- ----------------- -------------------- ------------------ --------------------------- -------------------------- --------------------------
  RANK rs1805034                                                                                                                    
  TC vs. TT        253/266           44.3/46.6            324/386            41.3/49.2                   1.13 (0.90, 1.42), 0.280   1.13 (0.90, 1.42); 0.287
  CC vs. TT        52/266            9.1/46.6             75/386             9.5/49.2                    1.01 (0.68, 1.48), 0.975   0.99 (0.77, 1.27); 0.992
  CC+TC vs. TT     305/266           53.4/46.6            399/386            50.8/49.2                   1.11 (0.89, 1.38), 0.347   1.11 (0.89, 1.37); 0.360
  CC vs. TC+TT     52/519            9.1/90.9             75/710             9.5/90.5                    0.95 (0.64, 1.38), 0.780   0.94 (0.65, 1.37); 0.749
  C vs. T          357/785           31.3/68.7            474/1096           30.2/69.8                   1.05 (0.89, 1.24), 0.551   NA

Adjusted for age and sex. Abbreviation: NA, not available.

Association between RANK gene rs1805034 polymorphism and RA risk {#sec3-2}
----------------------------------------------------------------

The genotypic distribution of the *RANK* gene rs1805034 polymorphism in all subjects are delineated in [Table 2](#T2){ref-type="table"}. Logistic regression analyses revealed that the CC genotype, or C allele carriers of the rs1805034 polymorphism, were not associated with the risk of RA (TC *vs.* TT; adjusted OR = 1.13, *P*=0.0287; CC *vs.* TT; adjusted OR = 0.99, *P*=0.992; CC+TC *vs.* TT; OR = 1.11, *P*=0.360; CC *vs.* TC+TT; adjusted OR = 0.94, *P*=0.749; C *vs.* T; OR = 1.05, *P*=0.551, [Table 2](#T2){ref-type="table"}). Furthermore, the effects of this SNP on RA risk were further evaluated according to age and sex; no significant association was found (Supplementary Table S1). Furthermore, no significant association was found between rs1805034 genotypes and clinical or biochemical characteristics. Finally, no significant differences were found in terms of demographic or laboratory data when compared between CC+TC and TT genotypes (Supplementary Table S2) or between CC and TC+TT genotypes (Supplementary Table S3 & Table S4).

Meta-analysis: general characteristics of the included studies and quantitative analysis {#sec3-3}
----------------------------------------------------------------------------------------

All included studies were carefully selected and our literature review was up-to-date as of July 2018. Our selection protocol for qualified studies is presented in [Figure 1](#F1){ref-type="fig"}. The characteristics of the studies included in this meta-analysis investigating the associations between the SNPs of *RANK, RANKL, OPG* genes and RA risk are listed in Supplementary Tables S5 and S6. Five Asian studies (including the present study) and four Caucasian studies, were identified for inclusion in this meta-analysis. The Newcastle--Ottawa Scale (NOS) scores of all included studies ranged from 5 to 7 stars, suggesting that they were studies of high methodological quality.

![Flowchart describing how the literature search was performed and how individual studies were selected for analysis](bsr-39-bsr20182356-g1){#F1}

Our meta-analysis indicated that the *RANK* rs1805034 polymorphism was not associated with the risk of RA (C *vs.* T: OR = 0.99, *P*=0.923; CC+TC *vs.* TT: OR = 0.99, *P*=0.927; CC *vs.* TC+TT: OR = 1.02, *P*=0.895; CC *vs.* TT: OR = 1.02, *P*=0.840; TC *vs.* TT: OR = 0.98, *P*=0.792, [Table 3](#T3){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}). Identical results were found when we carried out subgroup analysis by ethnicity and source of controls (SOC) (Supplementary Table S5 and [Figure 2](#F2){ref-type="fig"}). We did not identify any different conclusions after eliminating a study \[[@B9]\] which did not meet the HWE, indicating that the data arising from our meta-analysis are trustworthy and stable. The results of our sensitivity analysis indicated that our data were also stable and credible. Neither Egger's nor Begg's tests revealed obvious publication bias for the rs1805034 polymorphism (Supplementary Figure S1). General analysis showed that the *RANKL* gene rs2277438 polymorphism increased RA risk (G *vs*. A; OR = 1.21, *P*=0.047; GG *vs.* AG+AA; OR = 1.81, *P*=0.023; GG *vs.* AA; OR = 1.90, *P*=0.016; Supplementary Figure S2).

![Forest plot showing the OR for association between the rs1805034 polymorphism and the risk of RA\
(**A**) Forest plot showing the OR for associations between the rs1805034 polymorphism and the risk of RA (CC+TC *vs.* TT). (**B**) Stratification analysis by ethnicity showing the OR for associations between the rs1805034 polymorphism and RA risk (CC+TC *vs*. TT). (**C**) Stratification analysis by SOC showing the OR for associations between the rs1805034 polymorphism and the risk of RA (CC+TC *vs.* TT).](bsr-39-bsr20182356-g2){#F2}

###### Meta-analysis of the association between RANK, RANKL, OPG polymorphisms and RA risk

  SNP               Comparison     Category    Category     Studies   OR (95% CI)          *P*-value   *P* for heterogeneity
  ----------------- -------------- ----------- ------------ --------- -------------------- ----------- -----------------------
  RANK rs1805034    C vs. T        Total                    3         0.99 (0.83, 1.19)    0.923       0.102
                                   Ethnicity   Caucasians   2         0.92 (0.64, 1.34)    0.670       0.037
                                               Chinese      1         1.05 (0.89, 1.24)    0.551       --
                                   SOC         PB           1         0.75 (0.55, 1.02)    0.066       --
                                               HB           2         1.07 (0.95, 1.21)    0.267       0.766
                    CC+TC vs. TT   Total                    3         0.99 (0.85, 1.16)    0.927       0.172
                                   Ethnicity   Caucasians   2         0.88 (0.70, 1.10)    0.264       0.232
                                               Chinese      1         1.11 (0.89, 1.38)    0.347       --
                                   SOC         PB           1         0.71 (0.46, 1.06)    0.111       --
                                               HB           2         1.05 (0.89, 1.24)    0.590       0.406
                    CC vs. TC+TT   Total                    3         1.02 (0.72, 1.46)    0.895       0.092
                                   Ethnicity   Caucasians   2         1.02 (0.54, 1.91)    0.949       0.048
                                               Chinese      1         0.95 (0.64,1.38)     0.780       --
                                   SOC         PB           1         0.70 (0.40, 1.25)    0.228       --
                                               HB           2         1.15 (0.82, 1.62)    0.415       0.148
                    CC vs. TT      Total                    3         1.02 (0.81, 1.30)    0.840       0.163
                                   Ethnicity   Caucasians   2         0.91 (0.47, 1.76)    0.785       0.057
                                               Chinese      1         1.01 (0.68,1.48)     0.975       --
                                   SOC         PB           1         0.62 (0.34, 1.14)    0.123       --
                                               HB           2         1.18 (0.87, 1.45)    0.381       0.465
                    TC vs. TT      Total                    3         0.98 (0.83, 1.15)    0.792       0.158
                                   Ethnicity   Caucasians   2         0.83 (0.65, 1.05)    0.123       0.642
                                               Chinese      1         1.13 (0.90,1.42)     0.280       --
                                   SOC         PB           1         0.75 (0.47, 1.20)    0.228       --
                                               HB           2         1.00 (0.76, 1.31)    0.991       0.131
  RANKL rs2277438   G vs. A        Total                    2         1.21 (1.00, 1.45)    0.047       0.797
                    GG+AG vs. AA   Total                    2         1.16 (0.93, 1.45)    0.179       0.746
                    GG vs. AG+AA   Total                    2         1.81 (1.09, 3.02)    0.023       0.177
                    GG vs. AA      Total                    2         1.90 (1.13, 3.20)    0.016       0.243
                    AG vs. AA      Total                    2         1.08 (0.86, 1.36)    0.515       0.492
  OPG rs3102735     C vs. T        Total                    5         1.22 (0.86, 1.73)    0.260       \<0.001
                                   Ethnicity   Asians       3         1.01 (0.70, 1.46)    0.942       0.018
                                               Caucasians   2         1.62 (0.83, 3.13)    0.155       0.006
                                   SOC         HB           2         1.29 (1.04, 1.60)    0.023       0.251
                                               PB           3         1.16 (0.64, 2.13)    0.621       \<0.001
                    CC+TC vs. TT   Total                    5         1.16 (0.85, 1.59)    0.338       0.004
                                   Ethnicity   Asians       3         0.97 (0.71, 1.33)    0.849       0.104
                                               Caucasians   2         1.52 (0.88, 2.61)    0.132       0.046
                                   SOC         HB           2         1.25 (0.98, 1.59)    0.073       0.517
                                               PB           3         1.11 (0.65, 1.90)    0.703       0.002
                    CC vs. TC+TT   Total                    5         1.73 (0.67, 4.46)    0.254       0.005
                                   Ethnicity   Asians       3         1.21 (0.39, 3.72)    0.745       0.036
                                               Caucasians   2         3.04 (0.59, 15.70)   0.183       0.050
                                   SOC         HB           2         2.38 (0.74, 7.66)    0.145       0.171
                                               PB           3         1.43 (0.34, 4.46)    0.627       0.004
                    CC vs. TT      Total                    5         1.79 (0.65, 4.89)    0.259       0.002
                                   Ethnicity   Asians       3         1.20 (0.36, 3.93)    0.766       0.026
                                               Caucasians   2         3.30 (0.58, 18.72)   0.177       0.039
                                   SOC         HB           2         2.49 (0.76, 8.20)    0.133       0.164
                                               PB           3         1.46 (0.31, 6.93)    0.634       0.002
                    TC vs. TT      Total                    5         1.03 (0.88, 1.20)    0.728       0.136
                                   Ethnicity   Asians       3         0.91 (0.75, 1.10)    0.337       0.389
                                               Caucasians   2         1.27 (0.98, 1.64)    0.067       0.320
                                   SOC         HB           2         1.18 (0.92, 1.52)    0.190       0.920
                                               PB           3         0.94 (0.77, 1.15)    0.555       0.081
  OPG rs2073618     C vs. G        Total                    3         1.06 (0.95, 1.19)    0.295       0.998
                                   Ethnicity   Asians       2         1.07 (0.92, 1.24)    0.406       0.986
                                               Caucasians   1         1.06 (0.89, 1.26)    0.522       --
                                   SOC         PB           2         1.07 (0.92, 1.24)    0.406       0.986
                                               HB           1         1.06 (0.89, 1.26)    0.522       --
                    CC+GC vs. GG   Total                              1.10 (0.94, 1.30)    0.226       0.982
                                   Ethnicity   Asians       2         1.10 (0.91, 1.34)    0.303       0.851
                                               Caucasians   1         1.10 (0.81, 1.50)    0.525       --
                                   SOC         PB           2         1.10 (0.91, 1.34)    0.303       0.851
                                               HB           1         1.10 (0.81, 1.50)    0.525       --
                    CC vs. GC+GG   Total                              1.04 (0.84, 1.30)    0.709       0.896
                                   Ethnicity   Asians       2         1.00 (0.69, 1.46)    0.982       0.687
                                               Caucasians   1         1.06 (0.81, 1.39)    0.659       --
                                   SOC         PB           2         1.00 (0.69, 1.46)    0.982       0.687
                                               HB           1         1.06 (0.81, 1.39)    0.659       --
                    CC vs. GG      Total                              1.09 (0.84, 1.42)    0.503       0.915
                                   Ethnicity   Asians       2         1.05 (0.71, 1.55)    0.800       0.751
                                               Caucasians   1         1.13 (0.79, 1.62)    0.489       --
                                   SOC         PB           2         1.05 (0.71, 1.55)    0.800       0.751
                                               HB           1         1.13 (0.79, 1.62)    0.489       --
                    GC vs. GG      Total                              1.11 (0.94, 1.31)    0.237       0.945
                                   Ethnicity   Asians       2         1.11 (0.91, 1.36)    0.286       0.750
                                               Caucasians   1         1.09 (0.79, 1.51)    0.600       --
                                   SOC         PB           2         1.11 (0.91, 1.36)    0.286       0.750
                                               HB           1         1.09 (0.79, 1.51)    0.600       --
  OPG rs3134069     C vs. A        Total                    2         0.79 (0.50, 1.25)    0.310       0.787
                    CC+AC vs. AA   Total                    2         0.78 (0.48, 1.26)    0.305       0.580
                    CC vs. AC+AA   Total                    2         0.76 (0.13, 4.52)    0.766       0.434
                    CC vs. AA      Total                    2         0.72 (0.12, 4.33)    0.724       0.457
                    AC vs. AA      Total                    2         0.78 (0.47, 1.28)    0.320       0.435

Abbreviations: HB, hospital based; PB, public based.

Pooled analysis showed that *OPG* gene rs3102735/rs2073618/rs3134069 polymorphisms were not related to RA risk ([Table 3](#T3){ref-type="table"} and [Figure 3](#F3){ref-type="fig"}). Further stratification analyses by ethnicity (Supplementary Figure S3) and SOC revealed that rs3102735/rs2073618 polymorphisms were not associated with the risk of RA among Asians or Caucasians or hospital-based and public-based studies ([Table 3](#T3){ref-type="table"}).

![Forest plot showing the OR for associations between SNPs and RA risk\
(**A**) Forest plot showing the OR for associations between the rs3102735 polymorphism and RA risk (CC+TC *vs*. TT). (**B**) Forest plot showing the OR for associations between the rs2073618 polymorphism and the risk of RA (CC+GC *vs*. GG). (**C**) Forest plot showing the OR for associations between the rs3134069 polymorphism and the risk of RA (CC+AC *vs*. AA).](bsr-39-bsr20182356-g3){#F3}

Previous research investigated rs35211496, rs7984870, rs9525641, rs9533156, rs1054016, rs531564, rs2073617 and rs3134070 polymorphisms \[[@B9],[@B11],[@B12],[@B16]\] and reported some significant associations (Supplementary Table S6). Nevertheless, further studies are now required to confirm such associations.

Discussion {#sec4}
==========

This case-controlled study is the first study to explore the relationship between *RANK* gene rs1805034 polymorphism and the risk of RA in a Chinese Han population. The results indicated that rs1805034 polymorphism of *RANK* gene was not associated with the risk of RA. Stratification analyses by sex and age suggested that *RANK* gene rs1805034 polymorphism was not associated with the risk of RA among groups of male, female, age ≤ 55 and age \> 55. This meta-analysis found that the rs2277438 polymorphism in *RANKL* gene increased the risk of RA, whereas *RANK* gene rs1805034, *OPG* gene rs3102735, *OPG* gene rs2073618, *OPG* gene rs3134069 polymorphisms were not related to RA susceptibility. Inflammatory osteoporosis is a frequent finding in RA joints and is mediated by accelerated osteoclast recruitment and activation, induced via interactions with RANK and its ligand, RANKL \[[@B19]\]. OPG recognizes and binds to RANKL, blocking its interaction with RANK, thus inhibiting osteoclastic differentiation and activation \[[@B20]\]. The RANK/RANKL/OPG system therefore acts as a pivotal part of the immune system and cross-links this system to bone in what has become known as osteoimmunology, a new interdisciplinary field of study integrating the disciplines of immunology and bone biology, thus providing a new perspective on the pathogenesis of RA \[[@B23]\].

Several studies have investigated the association between SNPs in *RANK* and *RANKL, OPG* genes. Assmann et al. \[[@B12]\] were the first to conduct such research and found that the minor allele of the *RANK* SNP rs35211496 may be protective against RA in a German population, whereas the minor alleles of the *RANKL* SNP rs2277438 may increase susceptibility to RA. In a subsequent study from China, Zhang et al. \[[@B11]\] revealed that there was no significant difference in the distribution of genotype or allele frequency between control subjects and RA groups. Stratification analyses by sex, age, C-reactive protein (CRP) and anti-CCP status also indicated that the *RANKL* gene rs7984870 polymorphism was not related to RA risk. Xu et al. \[[@B10]\] further showed that the RANKL gene rs2277438 polymorphism may not be a susceptibility factor for RA in a Chinese Han population but may have an important influence on bone and joint injury in RA. The distinct distribution of allele frequency may explain the different findings of the work carried out by Assmann et al. \[[@B12]\] and Xu et al. \[[@B10]\]. Mohamed et al. \[[@B9]\] observed that T allele carriers of the *RANK* gene rs1805034 polymorphism increased the risk of RA in an Egyptian population. Both Assmann et al. \[[@B12]\] and Mohamed et al. \[[@B9]\] studied the association between the *RANK* gene rs1805034 polymorphism and RA risk in Caucasian populations, but no other ethnic groups were involved. Thus, we conducted a case-controlled study in a Chinese Han population and found that the *RANK* gene rs1805034 polymorphism was not related to RA risk; this was consistent with Assmann et al. \[[@B12]\] but not with Mohamed et al. \[[@B9]\] There are several possible reasons for these different findings regarding the rs1805034 polymorphism. First, the study designs were different. The study by Assman et al. \[[@B12]\] study included only postmenopausal females in the RA group. Second, genetic heterogeneity for RA is known to exist in different populations (Assman et al. \[[@B12]\] studied a central European population while Mohamed et al. \[[@B9]\] studied an Egyptian population). Third, these discrepancies may be explained by clinical heterogeneity. Finally, the sample size included in the study reported by Mohamed et al. \[[@B9]\] was not large enough compared with the work carried out by Assmann et al. \[[@B12]\] and our own study, relative to Caucasian populations to support a clear conclusion. Assmann et al. \[[@B12]\] first reported that *OPG* gene rs3102735 polymorphism was not associated with the risk of RA. Hussien et al. \[[@B13]\] conducted a case-controlled study (200 cases and 150 controls) and found that *OPG* gene rs3102735 polymorphism was associated with RA susceptibility and the occurrence and development of osteoporosis in RA patients. Xu et al. \[[@B10]\] and Ye et al. \[[@B15]\] found that *OPG* gene rs3102735 polymorphism was not related to the risk of RA, whereas Cai et al. \[[@B14]\] reported that *OPG* gene rs3102735 polymorphism increased the risk of RA. Sample size, genetic diversity and clinical heterogeneity may explain the results of contradictions.

We realized that a single case--control study could be underpowered and inconclusive, so we carried out an additional meta-analysis together with our own case--control study. Eight published case--control studies, including 2296 cases and 2769 controls, were combined with our data to perform this meta-analysis. This represents the first meta-analysis to investigate the association between all known SNPs in *RANK/RANKL* genes and RA risk. Our meta-analysis indicated that the *RANK* gene rs1805034 polymorphism was not associated with the risk of RA, which was consistent with our own study. We also found that the *RANKL* gene rs2277438 polymorphism increased the risk of RA. To better understand the role that the RANK/RANKL/OPG network plays in the pathogenesis of RA, all reported SNPs in the *OPG* gene were also included in this meta-analysis. According to our data, *OPG* gene rs3102735, *OPG* gene rs2073618 and *OPG* gene rs3134069 polymorphisms were not related to RA susceptibility. Chen et al. \[[@B26]\] also performed a meta-analysis including five case-controlled studies to verify the association between these SNPs and RA risk and obtained the same results. Compared with the meta-analysis by Chen et al. \[[@B26]\], we consider that our meta-analysis had several additional advantages. First, our meta-analysis for the rs3134069 polymorphism included one more case-controlled study. Second, subgroup analyses were conducted by ethnicity and SOC for rs3102735 and rs2073618 polymorphisms in our meta-analysis. No significant results were found, indicating that our findings were more trustworthy.

Several potential limitations of this case--control study and meta-analysis should be considered when interpreting our results. First, we were unable to analyze subgroups of some confounding factors due to the lack of corresponding data. Second, our results were based on unadjusted estimates for confounding factors. Third, the studies included only involved Asians and Caucasians; studies among other racial groups are urgently needed. Fourth, our conclusions relating to some stratification analyses of the rs1805034 polymorphisms should be interpreted with caution, owing to limited sample size. Fifth, clinical cases should be investigated in further studies to support these analytical results. Finally, five genetic models of inheritance were used herein; thus, type I error may have arisen through a lack of correction for multiple testing.

In conclusion, this case-controlled study and meta-analysis indicated that the *RANKL* gene rs2277438 polymorphism increased the RA risk, and that *RANK* gene rs1805034, OPG gene rs3102735, OPG gene rs2073618, OPG gene rs3134069 polymorphisms were not related to RA risk. More clinical cases should now be investigated in further studies to support these analytical results.
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